Proactive Investors - Run By Investors For Investors

BriaCell having discussions with pharma companies on combination therapies

BriaCell Therapeutics (OTCQB: BCTXF) CEO Bill Williams sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizuma. BriaCell is also developing Bria-OTS, a personalized immunotherapy to treat advanced breast cancer.

View full BCT profile View Profile

Briacell Therapeutics Corp Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use